Prime Medicine: Soon In The Clinic (NASDAQ:PRME)
· seekingalpha.com
Prime Medicine stock analysis: a $548M valuation vs. a best-in-class gene-editing pipeline, key catalysts, M&A upside, and dilution risks. Click to read more.
Prime Medicine ( PRME ) is a small biotechnology company valued at around $548 million. Their stock price has not had the best few months, with it being down 54...